Authors: Bestehorn, K.; Wahle, Klaus

Source: Clinical Drug Investigation, Volume 27, Number 5, 2007 , pp. 347-355(9)

Publisher: Adis International

Abstract:

Background and objective: While a number of conditions and risk factors that increase stroke risk have been identified, arterial hypertension is the most consistent and powerful predictor. The angiotensin II type 1 receptor antagonist (angio-tensin receptor blocker [ARB]) losartan has been shown in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study to decrease stroke risk in hypertensive patients to a substantially greater extent than conventional therapy. We aimed to assess the impact of the blood pressure-lowering effect of losartan therapy on stroke risk in hypertensive patients in primary care.

Methods: A total of 2977 primary-care practices throughout Germany included 22 499 consecutive unselected patients with a confirmed diagnosis of hypertension in an open-label, prospective, observational study. In addition to demographics, known risk factors for stroke were documented on standardised questionnaires. The 10-year predicted risk of first stroke was calculated according to the Framingham Stroke Risk Score at baseline and after a mean of 94 ± 24 days of losartan (± hydrochlorothiazide [HCTZ]) therapy.

Results: The mean patient age was 64.1 ± 10.6 years, and 52.4% were males. Mean systolic/diastolic blood pressure decreased from 160 ± 15/93 ± 9mm Hg at baseline by -21 ± 14/-11 ± 9mm Hg. Besides hypertension, 84.9% of patients had other co-morbidities, of which the most frequent were hypercholesterolaemia (53.0%), diabetes mellitus (36.1%), coronary heart disease (31.1%) and left ventricular hypertrophy (24.2%). The average predicted 10-year stroke risk was 28.0 ± 21.9% at baseline, and 22.1 ± 19.5% at study end (relative risk reduction 24 ± 16%, p < 0.05). In subgroups of patients with diabetes or nephropathy, similar effects were noted. Drug-related adverse events were reported in 18 patients; all of these were non-serious.

Conclusion: Because of the high prevalence of co-morbidities and risk factors, the hypertensive patient population observed in this study presented with a high 10-year stroke risk. Treatment with losartan (± HCTZ) was well tolerated and led to a substantial decrease in blood pressure and associated stroke risk.

Keywords: Angiotensin II 1 receptor antagonists; Hypertension; Losartan; Stroke

Document Type: Research article

Affiliations: 1: 3 Institute for Practice Research, German Primary Care Physician Association (BDA), Nittendorf, Germany

Publication date: 2007-01-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Bestehorn, K. ;  Wahle, Klaus

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers